Immunomic Therapeutics, Inc. (ITI) and Nature Technology Corporation (NTC) announce today that they have entered into a new license agreement. The licensing of NTC’s RNA-OUT™ and HyperGro™ technology is part of ITI’s expansion into developing nucleic acid immunotherapies for cancer.
ITI believes that LAMP-Vax immunotherapy platform has the potential to transform nucleic acid vaccine therapy. Although additional studies are needed to confirm clinical benefit, LAMP-Vax has the potential to specifically direct the cancer antigen into a processing part of the cell for more efficient presentation to the immune system. Last year, this approach gained important commercial validation when Immunomic Therapeutics entered into significant licensing agreements with Astellas Pharma Inc., totaling over $315 million in upfront payments, as well as potential future milestones and royalty payments.